Controversy surrounding the use of the prostate-specific antigen (PSA) test as a Prostate Cancer (PCa) screening tool is mainly related to the probability of overdiagnosis and overtreatment of indolent cancers [1]. This evidence concerns the gene KLK3 and posterior cortical atrophy.